View Item 

Show simple item record

Consensus report from the 6th International forum for liver MRI using gadoxetic acid
dc.contributor.authorSirlin, Claude B.en_US
dc.contributor.authorHussain, Hero K.en_US
dc.contributor.authorJonas, Eduarden_US
dc.contributor.authorKanematsu, Masayukien_US
dc.contributor.authorMin Lee, Jeongen_US
dc.contributor.authorMerkle, Elmar M.en_US
dc.contributor.authorPeck‐radosavljevic, Markusen_US
dc.contributor.authorReeder, Scott B.en_US
dc.contributor.authorRicke, Jensen_US
dc.contributor.authorSakamoto, Michiieen_US
dc.date.accessioned2014-09-03T16:51:29Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-09-03T16:51:29Z
dc.date.issued2014-09en_US
dc.identifier.citationSirlin, Claude B.; Hussain, Hero K.; Jonas, Eduard; Kanematsu, Masayuki; Min Lee, Jeong; Merkle, Elmar M.; Peck‐radosavljevic, Markus ; Reeder, Scott B.; Ricke, Jens; Sakamoto, Michiie (2014). "Consensus report from the 6th International forum for liver MRI using gadoxetic acid." Journal of Magnetic Resonance Imaging 40(3): 516-529.en_US
dc.identifier.issn1053-1807en_US
dc.identifier.issn1522-2586en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108276
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherHepatocellular Carcinoma Management Guidelinesen_US
dc.subject.otherCirrhosisen_US
dc.subject.otherInternational Forum for Liver MRIen_US
dc.subject.otherConsensus Reporten_US
dc.subject.otherGadoxetic Disodiumen_US
dc.subject.otherLiver Functionen_US
dc.subject.otherLiver Metastasesen_US
dc.subject.otherGadoxetic Aciden_US
dc.titleConsensus report from the 6th International forum for liver MRI using gadoxetic aciden_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108276/1/jmri24419.pdf
dc.identifier.doi10.1002/jmri.24419en_US
dc.identifier.sourceJournal of Magnetic Resonance Imagingen_US
dc.identifier.citedreferenceTakayama Y, Nishie A, Nakayama T, et al. Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid‐enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 2012; 81: 3072 – 3078.en_US
dc.identifier.citedreferenceAkai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd‐EOB‐DTPA‐enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011; 80: 310 – 315.en_US
dc.identifier.citedreferenceInoue T, Kudo M, Komuta M, et al. Assessment of Gd‐EOB‐DTPA‐enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47: 1036 – 1047.en_US
dc.identifier.citedreferenceLeoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599 – 609.en_US
dc.identifier.citedreferenceBolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27 – 34.en_US
dc.identifier.citedreferenceForner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245 – 1255.en_US
dc.identifier.citedreferenceMazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35 – 43.en_US
dc.identifier.citedreferenceLencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52 – 60.en_US
dc.identifier.citedreferenceHwang J, Kim SH, Kim YS, et al. Gadoxetic acid‐enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image‐guided tumor therapy. J Magn Reson Imaging 2010; 32: 629 – 638.en_US
dc.identifier.citedreferenceChong YS, Kim YK, Lee MW, et al. Differentiating mass‐forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid‐enhanced MRI. Clin Radiol 2012; 67: 766 – 773.en_US
dc.identifier.citedreferenceKim SH, Lee CH, Kim BH, et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid‐enhanced magnetic resonance imaging. J Comput Assist Tomogr 2012; 36: 704 – 709.en_US
dc.identifier.citedreferenceKim YK, Kim CS, Han YM, Yu HC, Choi D. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid‐enhanced MRI at 3.0 and 1.5 T. Invest Radiol 2011; 46: 383 – 389.en_US
dc.identifier.citedreferenceBaek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid‐enhanced MRI and multiphasic MDCT. Clin Radiol 2012; 67: 148 – 156.en_US
dc.identifier.citedreferenceChou CT, Chen YL, Su WW, Wu HK, Chen RC. Characterization of cirrhotic nodules with gadoxetic acid‐enhanced magnetic resonance imaging: the efficacy of hepatocyte‐phase imaging. J Magn Reson Imaging 2010; 32: 895 – 902.en_US
dc.identifier.citedreferenceDoo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM. “Pseudo washout” sign in high‐flow hepatic hemangioma on gadoxetic acid contrast‐enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009; 193: W490 – W496.en_US
dc.identifier.citedreferenceFrericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd‐EOB‐DTPA. AJR Am J Roentgenol 2009; 193: 1053 – 1060.en_US
dc.identifier.citedreferenceGolfieri R, Grazioli L, Orlando E, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd‐EOB‐DTPA administration. J Magn Reson Imaging 2012; 36: 648 – 657.en_US
dc.identifier.citedreferenceGoshima S, Kanematsu M, Watanabe H, et al. Gadoxetate disodium‐enhanced MR imaging: differentiation between early‐enhancing non‐tumorous lesions and hypervascular hepatocellular carcinomas. Eur J Radiol 2011; 79: e108 – e112.en_US
dc.identifier.citedreferenceHwang J, Kim SH, Lee MW, Lee JY. Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid‐enhanced 3.0 T MRI and multiphasic 64‐multirow detector CT. Br J Radiol 2012; 85: e314 – e322.en_US
dc.identifier.citedreferenceJung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd‐EOB‐DTPA. Acta Radiol 2006; 47: 15 – 23.en_US
dc.identifier.citedreferenceKim YK, Kim CS, Han YM, Park G. Detection of small hepatocellular carcinoma: can gadoxetic acid‐enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine‐enhanced and superparamagnetic iron oxide‐enhanced magnetic resonance imaging? Invest Radiol 2010; 45: 740 – 746.en_US
dc.identifier.citedreferenceKim YK, Kim CS, Han YM, Park G, Hwang SB, Yu HC. Comparison of gadoxetic acid‐enhanced MRI and superparamagnetic iron oxide‐enhanced MRI for the detection of hepatocellular carcinoma. Clin Radiol 2010; 65: 358 – 365.en_US
dc.identifier.citedreferenceLee S, Kim SH, Park CK, Kim YS, Lee WJ, Lim HK. Comparison between areas with Gd‐EOB‐DTPA uptake and without in hepatocellular carcinomas on Gd‐EOB‐DTPA‐enhanced hepatobiliary‐phase MR imaging: pathological correlation. J Magn Reson Imaging 2010; 32: 719 – 725.en_US
dc.identifier.citedreferenceMarin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine‐enhanced MR imaging and multiphasic 64‐section CT. Radiology 2009; 251: 85 – 95.en_US
dc.identifier.citedreferenceMita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010; 16: 4187 – 4192.en_US
dc.identifier.citedreferenceOnishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium‐enhanced MR imaging and multiphasic multidetector CT. Eur Radiol 2012; 22: 845 – 854.en_US
dc.identifier.citedreferencePark Y, Kim SH, Kim SH, et al. Gadoxetic acid (Gd‐EOB‐DTPA)‐enhanced MRI versus gadobenate dimeglumine (Gd‐BOPTA)‐enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010; 11: 433 – 440.en_US
dc.identifier.citedreferenceRhee H, Kim MJ, Park YN, Choi JS, Kim KS. Gadoxetic acid‐enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria. J Magn Reson Imaging 2012; 35: 393 – 398.en_US
dc.identifier.citedreferenceSano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid‐enhanced MR imaging. Radiology 2011; 261: 834 – 844.en_US
dc.identifier.citedreferenceShinagawa Y, Sakamoto K, Fujimitsu R, et al. Pseudolesion of the liver observed on gadoxetate disodium‐enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol 2010; 28: 483 – 488.en_US
dc.identifier.citedreferenceSuh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid‐enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 2011; 197: W44 – W52.en_US
dc.identifier.citedreferenceBelghiti J, Hiramatsu K, Benoist S, Massault PP, Sauvanet A, Farges O. Seven hundred forty‐seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection (abstract). J Am Coll Surg 2000; 191: 38 – 46.en_US
dc.identifier.citedreferenceJarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397 – 406.en_US
dc.identifier.citedreferenceKarlo C, Reiner CS, Stolzmann P, et al. CT‐ and MRI‐based volumetry of resected liver specimen: comparison to intraoperative volume and weight measurements and calculation of conversion factors (abstract). Eur J Radiol 2010; 75: e107 – e111.en_US
dc.identifier.citedreferenceBreitenstein S, Apestegui C, Petrowsky H, Clavien PA. “State of the art” in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg 2009; 33: 797 – 803.en_US
dc.identifier.citedreferenceZorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev 2007; 31: 49 – 60.en_US
dc.identifier.citedreferenceGuglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg 2012; 29: 6 – 17.en_US
dc.identifier.citedreferenceSeyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res 2009; 39: 107 – 116.en_US
dc.identifier.citedreferenceMorris‐Stiff G, Gomez D, Prasad R. Quantitative assessment of hepatic function and its relevance to the liver surgeon. J Gastrointest Surg 2009; 13: 374 – 385.en_US
dc.identifier.citedreferenceEuropean Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL‐EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma (abstract). J Hepatol 2012; 56: 908 – 943.en_US
dc.identifier.citedreferenceKudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus‐based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339 – 364.en_US
dc.identifier.citedreferenceMakuuchi M, Kokudo N, Arii S, et al. Development of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37 – 51.en_US
dc.identifier.citedreferenceAbdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and segmental liver volume variations: implications for liver surgery (abstract). Surgery 2004; 135: 404 – 410.en_US
dc.identifier.citedreferencede Graaf W, van Lienden KP, Dinant S, et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg 2010; 14: 369 – 378.en_US
dc.identifier.citedreferenceBennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM. Liver function testing with nuclear medicine techniques is coming of age (abstract). Semin Nucl Med 2012; 42: 124 – 137.en_US
dc.identifier.citedreferenceBonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? (abstract). J Hepatol 2009; 50: 17 – 35.en_US
dc.identifier.citedreferenceHeye T, Yang SR, Bock M, et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012; 22: 1224 – 1232.en_US
dc.identifier.citedreferenceTam HH, Collins DJ, Wallace T, Brown G, Riddell A, Koh DM. Segmental liver hyperintensity in malignant biliary obstruction on diffusion weighted MRI: associated MRI findings and relationship with serum alanine aminotransferase levels. Br J Radiol 2012; 85: 22 – 28.en_US
dc.identifier.citedreferenceVan Beers BE, Pastor CM, Hussain HK. Primovist, eovist: what to expect? (abstract). J Hepatol 2012; 57: 421 – 429.en_US
dc.identifier.citedreferenceCho SH, Kang UR, Kim JD, Han YS, Choi DL. The value of gadoxetate disodium‐enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study. Eur J Radiol 2011; 80: e195 – e200.en_US
dc.identifier.citedreferenceKatsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging. Invest Radiol 2011; 464: 277 – 283.en_US
dc.identifier.citedreferenceKatsube T, Okada M, Kumano S, et al. Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol 2012; 81: 1460 – 1464.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liver‐enhancement ratio of gadoxetic acid‐enhanced MR imaging: comparison with aspartate aminotransferase‐to‐platelet ratio index. Magn Reson Imaging 2011; 29: 1047 – 1052.en_US
dc.identifier.citedreferenceTamada T, Ito K, Higaki A, et al. Gd‐EOB‐DTPA‐enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 2011; 80: e311 – e316.en_US
dc.identifier.citedreferenceYamada A, Hara T, Li F, et al. Quantitative evaluation of liver function with use of gadoxetate disodium‐enhanced MR imaging. Radiology 2011; 260: 727 – 733.en_US
dc.identifier.citedreferenceNilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte‐specific contrast‐enhanced MRI. J Magn Reson Imaging 2009; 29: 1323 – 1331.en_US
dc.identifier.citedreferenceNilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E. Assessment of liver function in primary biliary cirrhosis using Gd‐EOB‐DTPA‐enhanced liver MRI. HPB (Oxford) 2010; 12: 567 – 576.en_US
dc.identifier.citedreferenceSourbron S, Sommer WH, Reiser MF, Zech CJ. Combined quantification of liver perfusion and function with dynamic gadoxetic acid‐enhanced MR imaging. Radiology 2012; 263: 874 – 883.en_US
dc.identifier.citedreferencevan den Broek MA, van Dam RM, Malago M, Dejong CH, van Breukelen GJ, Olde Damink SW. Feasibility of randomized controlled trials in liver surgery using surgery‐related mortality or morbidity as endpoint. Br J Surg 2009; 96: 1005 – 1014.en_US
dc.identifier.citedreferenceWright M, Tidy C. Liver tumours. Patient.co.uk. Available at: http://www.patient.co.uk/doctor/Liver‐Tumours.htm. Accessed October 16, 2012.en_US
dc.identifier.citedreferenceSemelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218: 27 – 38.en_US
dc.identifier.citedreferenceNino‐Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA. Focal liver lesions: pattern‐based classification scheme for enhancement at arterial phase CT. Radiology 2000; 215: 746 – 751.en_US
dc.identifier.citedreferenceSemelka RC, Hussain SM, Marcos HB, Woosley JT. Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings‐initial observations. Radiology 2000; 215: 89 – 94.en_US
dc.identifier.citedreferenceScurr ED, Collins DJ, Temple L, Karanjia N, Leach MO, Koh DM. Appearances of colorectal hepatic metastases at diffusion‐weighted MRI compared with histopathology: initial observations. Br J Radiol 2012; 85: 225 – 230.en_US
dc.identifier.citedreferenceKele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010; 16: 1567 – 1576.en_US
dc.identifier.citedreferenceDanet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003; 181: 809 – 817.en_US
dc.identifier.citedreferenceNiekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta‐analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674 – 684.en_US
dc.identifier.citedreferenceJeong HT, Kim MJ, Park MS, et al. Detection of liver metastases using gadoxetic‐enhanced dynamic and 10‐ and 20‐minute delayed phase MR imaging. J Magn Reson Imaging 2012; 35: 635 – 643.en_US
dc.identifier.citedreferenceIchikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium‐enhanced magnetic resonance imaging and contrast‐enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133 – 141.en_US
dc.identifier.citedreferenceRaman SS, Leary C, Bluemke DA, et al. Improved characterization of focal liver lesions with liver‐specific gadoxetic acid disodium‐enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 2010; 34: 163 – 172.en_US
dc.identifier.citedreferenceKim YK, Park G, Kim CS, Yu HC, Han YM. Diagnostic efficacy of gadoxetic acid‐enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector‐row CT. Br J Radiol 2012; 85: 539 – 547.en_US
dc.identifier.citedreferenceKim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion‐weighted single‐shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999; 173: 393 – 398.en_US
dc.identifier.citedreferenceKoh DM, Collins DJ, Wallace T, Chau I, Riddell AM. Combining diffusion‐weighted MRI with Gd‐EOB‐DTPA‐enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 2012; 85: 980 – 989.en_US
dc.identifier.citedreferenceNagle SK, Busse RF, Brau AC, et al. High resolution navigated three‐dimensional T(1) ‐weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 tesla. J Magn Reson Imaging 2012; 36: 890 – 899.en_US
dc.identifier.citedreferenceBashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM. Liver MRI in the hepatocyte phase with gadolinium‐EOB‐DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging 2012; 35: 611 – 616.en_US
dc.identifier.citedreferenceAhn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid‐enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459 – 466.en_US
dc.identifier.citedreferenceDi Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium‐enhanced MR imaging and 64‐section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806 – 816.en_US
dc.identifier.citedreferenceGolfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd‐EOB‐DTPA‐enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233 – 1242.en_US
dc.identifier.citedreferenceHaradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid‐DTPA‐enhanced hepatobiliary phase MR imaging in the diagnosis of early‐stage hepatocellular carcinoma: comparison with dynamic triple‐phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69 – 78.en_US
dc.identifier.citedreferenceKim SH, Kim SH, Lee J, et al. Gadoxetic acid‐enhanced MRI versus triple‐phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192: 1675 – 1681.en_US
dc.identifier.citedreferenceSun HY, Lee JM, Shin CI, et al. Gadoxetic acid‐enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≤2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96 – 103.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid‐enhanced MR imaging. Radiology 2010; 256: 151 – 158.en_US
dc.identifier.citedreferenceKobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid‐enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011; 35: 181 – 186.en_US
dc.identifier.citedreferenceKumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium‐enhanced MRI. AJR Am J Roentgenol 2011; 197: 58 – 63.en_US
dc.identifier.citedreferenceFilippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte‐specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356 – 364.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Sano K, et al. Double‐dose gadoxetic Acid‐enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011; 46: 141 – 145.en_US
dc.identifier.citedreferenceHigaki A, Tamada T, Sone T, et al. Potential clinical factors affecting hepatobiliary enhancement at Gd‐EOB‐DTPA‐enhanced MR imaging. Magn Reson Imaging 2012; 30: 689 – 693.en_US
dc.identifier.citedreferenceKanki A, Tamada T, Higaki A, et al. Hepatic parenchymal enhancement at Gd‐EOB‐DTPA‐enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012; 30: 356 – 360.en_US
dc.identifier.citedreferenceKubota K, Tamura T, Aoyama N, et al. Correlation of liver parenchymal gadolinium‐ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. Oncol Lett 2012; 3: 990 – 994.en_US
dc.identifier.citedreferenceNakamura S, Awai K, Utsunomiya D, et al. Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd‐EOB‐DTPA‐enhanced 3‐T MR imaging: does liver function correlate with enhancement? Jpn J Radiol 2012; 30: 25 – 33.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Muhi A, et al. Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic Acid‐enhanced hepatocyte‐phase magnetic resonance imaging in patients with type C hepatitis and child‐pugh class a disease. Invest Radiol 2012; 47: 566 – 570.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte‐phase images in Gd‐EOB‐DTPA‐enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042 – 1046.en_US
dc.identifier.citedreferenceTajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid‐enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362 – 366.en_US
dc.identifier.citedreferenceGschwend S, Ebert W, Schultze‐Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd‐EOB‐DTPA in patients with hepatic and renal impairment. Invest Radiol 2011; 46: 556 – 566.en_US
dc.identifier.citedreferenceKim HY, Choi JY, Park CH, et al. Clinical factors predictive of insufficient liver enhancement on the hepatocyte‐phase of Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging in patients with liver cirrhosis. J Gastroenterol [Epub ahead of print].en_US
dc.identifier.citedreferenceTschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast‐enhanced MR cholangiography with Gd‐EOB‐DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577 – 1586.en_US
dc.identifier.citedreferenceTsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte‐selective enhancement at gadoxetic acid‐enhanced MR imaging‐‐correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824 – 833.en_US
dc.identifier.citedreferenceTsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi‐‐gadoxetic acid‐enhanced MR imaging. Radiology 2010; 256: 767 – 773.en_US
dc.identifier.citedreferenceKim MJ, Rhee HJ, Jeong HT. Hyperintense lesions on gadoxetate disodium‐enhanced hepatobiliary phase imaging. AJR Am J Roentgenol 2012; 199: W575 – W586.en_US
dc.identifier.citedreferenceKobayashi S, Matsui O, Gabata T, et al. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd‐EOB‐DTPA)‐enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012; 81: 3002 – 3009.en_US
dc.identifier.citedreferenceSano K, Motosugi U, Ichikawa T, Morisaka H, Ichikawa S, Araki T. The outcome of hypovascular nodules showing hyperintense on hepatocyte‐phase of gadoxetic acid‐enhanced magnetic resonance imaging: when does it become a conventional HCC? 4 years follow‐up study. In: Proceedings of the Annual Meeting of Radiological Society of North America, Chicago, November 25–30, 2012.en_US
dc.identifier.citedreferenceBartolozzi C, Battaglia V, Bargellini I, et al. Contrast‐enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdominal Imaging 2013; 38: 290 – 296.en_US
dc.identifier.citedreferenceNakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995; 22: 101 – 105.en_US
dc.identifier.citedreferenceTakayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28: 1241 – 1246.en_US
dc.identifier.citedreferenceKogita S, Imai Y, Okada M, et al. Gd‐EOB‐DTPA‐enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405 – 2413.en_US
dc.identifier.citedreferenceSugitani S, Sakamoto M, Ichida T, Genda T, Asakura H, Hirohashi S. Hyperplastic foci reflect the risk of multicentric development of human hepatocellular carcinoma. J Hepatol 1998; 28: 1045 – 1053.en_US
dc.identifier.citedreferenceMotosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34: 88 – 94.en_US
dc.identifier.citedreferenceAkai H, Matsuda I, Kiryu S, et al. Fate of hypointense lesions on Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging. Eur J Radiol 2012; 81: 2973 – 2977.en_US
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020 – 1022.en_US
dc.identifier.citedreferencePark G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid‐enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010; 83: 1010 – 1016.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jmri24419.pdf
Size:
377.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.